Abbott Labs continues Dx winning streak with bladder cancer biomarker deal

Abbott Laboratories' ($ABT) diagnostics unit posted sizable gains in 2014, and the company is continuing to chart positive momentum in the new year with a licensing deal with the Institut Curie. Under the agreement, Abbott will gain exclusive rights for FGFR3 gene mutations for use in bladder cancer, helping the company expand its footprint in molecular diagnostics. Release

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.